These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 32271462)
1. Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2? Bizzarri M; Laganà AS; Aragona D; Unfer V Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3426-3432. PubMed ID: 32271462 [TBL] [Abstract][Full Text] [Related]
2. May IL-17 have a role in COVID-19 infection? Megna M; Napolitano M; Fabbrocini G Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777 [No Abstract] [Full Text] [Related]
3. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Almerie MQ; Kerrigan DD Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562 [TBL] [Abstract][Full Text] [Related]
4. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology. Dal Moro F; Livi U Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196 [No Abstract] [Full Text] [Related]
6. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial. Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A; Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496 [TBL] [Abstract][Full Text] [Related]
7. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome. Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN Front Immunol; 2020; 11():1942. PubMed ID: 32983123 [TBL] [Abstract][Full Text] [Related]
8. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications. Smetana K; Brábek J In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815 [TBL] [Abstract][Full Text] [Related]
9. IL-6: Relevance for immunopathology of SARS-CoV-2. Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759 [TBL] [Abstract][Full Text] [Related]
10. Purposing Saikosaponins for the treatment of COVID-19. Bahbah EI; Negida A; Nabet MS Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743 [No Abstract] [Full Text] [Related]
11. Dapsone and doxycycline could be potential treatment modalities for COVID-19. Farouk A; Salman S Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778 [No Abstract] [Full Text] [Related]
12. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. Caron P Ann Endocrinol (Paris); 2020 Oct; 81(5):507-510. PubMed ID: 32950466 [TBL] [Abstract][Full Text] [Related]
13. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Zhang C; Wu Z; Li JW; Zhao H; Wang GQ Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467 [TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the López-Iranzo FJ; López-Rodas AM; Franco L; López-Rodas G Curr Pharm Des; 2020; 26(35):4515-4521. PubMed ID: 32787748 [TBL] [Abstract][Full Text] [Related]
15. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer. Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G Front Immunol; 2020; 11():588724. PubMed ID: 33117402 [TBL] [Abstract][Full Text] [Related]
16. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
17. Proposed use of thalidomide for the cytokine storm of COVID-19. Goihman-Yahr M Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614 [No Abstract] [Full Text] [Related]
18. Colorectal surgery obesity-related morbidity during COVID-19. Montorfano L; Miret R; Rahman AU; Alonso M; Maron DJ; Roy M; Ferri F; Bejarano P; Wexner SD Surg Obes Relat Dis; 2020 Sep; 16(9):1372-1375. PubMed ID: 32723601 [TBL] [Abstract][Full Text] [Related]
19. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment? Costiniuk CT; Jenabian MA Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020 [No Abstract] [Full Text] [Related]
20. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. Beyazit F; Beyazit Y; Tanoglu A; Haznedaroglu IC Med Hypotheses; 2020 Oct; 143():110150. PubMed ID: 32763660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]